Showing results (201-210 of 232) with videos related to
Sort By:
Pageof 24
British Journal of Pharmacology|April 18, 2009
Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiologyA K Bassil, C M Taylor, V J N Bolton, et al.British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.Journal of Medicinal Chemistry|April 5, 2018
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)Michael P Smolinski, Yahao Bu, James Clements, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1997
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administrationD Pajkrt, L Camoglio, M C Tiel-van Buul, et al.Cancer Research|April 15, 2000
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activityA A Adjei, C Erlichman, J N Davis, et al.Cancer Investigation|October 21, 2011
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancerNan Soon Wong, Kellen L Meadows, Lee S Rosen, et al.Pain|April 27, 2001
Orexin-A, an hypothalamic peptide with analgesic propertiesS Bingham, P T Davey, A J Babbs, et al.Journal of Clinical Immunology|September 1, 1996
Clinical, hematologic, and immunologic effects of interleukin-10 in humansA C Fuchs, E V Granowitz, L Shapiro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2022
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast CancerHope S Rugo, Gerardo A Umanzor, Francisco J Barrios, et al.Clinical and Translational Science|March 26, 2018
Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of ErtugliflozinSangeeta Raje, Ernesto Callegari, Vaishali Sahasrabudhe, et al.Pageof 24